Ubs Asset Management Americas Inc Dyne Therapeutics, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 143,363 shares of DYN stock, worth $1.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
143,363
Previous 134,334
6.72%
Holding current value
$1.89 Million
Previous $4.83 Million
30.01%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$106 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$97.3 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$97.2 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$88.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$84 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $682M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...